The approval of ETNA™-MS by Health Canada, developed by Innodem Neurosciences and associated with Novartis Pharmaceuticals Canada, could potentially strengthen Novartis' position in the multiple sclerosis treatment market by offering a novel tool for disease progression tracking. This regulatory milestone may positively influence Novartis' stock in the short term as it highlights the company's commitment to advancing MS care and could lead to increased interest and adoption of the technology.